Moreover, inhibition of acid ceramidase in GC-ase deficient patient-derived dopaminergic neurons resulted in increased ceramide, and decreased glycosylsphingosine levels eventually reduced oxidized α-Syn levels suggesting acid ceramidase inhibition as a potential therapeutic strategy for synucleinopathies linked to GBA1 mutations [75]. Here, ASAH1 is linked to synucleinopathy.